Show simple item record

dc.contributor.authorIoannidis, J. P. A.en
dc.contributor.authorPolycarpou, A.en
dc.contributor.authorNtais, C.en
dc.contributor.authorPavlidis, Nicholasen
dc.creatorIoannidis, J. P. A.en
dc.creatorPolycarpou, A.en
dc.creatorNtais, C.en
dc.creatorPavlidis, Nicholasen
dc.date.accessioned2018-06-22T09:53:41Z
dc.date.available2018-06-22T09:53:41Z
dc.date.issued2003
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41971
dc.description.abstractWe systematically evaluated the evidence from randomised trials comparing various chemotherapy regimens for advanced non-small cell lung cancer. Across 254 eligible trials (42 661 patients), no regimens were compared in >6 studies. Twenty-six trials (10%) found statistically significant differences in survival between the compared arms. Only five reported the randomisation mode, and four reported adequate allocation concealment; nine performed unaccounted interim analyses. Statistical significance was more common in larger (P=0.003), more recent studies (P=0.031), and trials from countries with only one published eligible study (P=0.008). Increased reported median survival was independently associated with platinum and/or taxane and combination regimens, but also with the year of publication, smaller sample size, and larger representation of non-stage IV patients and patients with a better performance status. The proportion of enrolled patients with a performance status of 2 or worse decreased significantly over time (12.9% per decade, P<0.001). Randomised evidence in this field is fragmented and subject to considerable selection biases. © 2003 Elsevier Ltd. All rights reserved.en
dc.language.isoengen
dc.sourceEuropean journal of canceren
dc.subjectBiasen
dc.subjectMeta-analysisen
dc.subjectAntineoplastic agenten
dc.subjectCisplatinen
dc.subjectCyclophosphamideen
dc.subjectDoxorubicinen
dc.subjectEtoposideen
dc.subjectHumanen
dc.subjectMethotrexateen
dc.subjectVinblastineen
dc.subjectControlled studyen
dc.subjectAdvanced canceren
dc.subjectCancer combination chemotherapyen
dc.subjectCancer survivalen
dc.subjectCarboplatinen
dc.subjectPaclitaxelen
dc.subjectPriority journalen
dc.subjectClinical trialen
dc.subjectControlled clinical trialen
dc.subjectGemcitabineen
dc.subjectNavelbineen
dc.subjectDrug dose regimenen
dc.subjectRandomized controlled trialen
dc.subjectStatistical significanceen
dc.subjectReviewen
dc.subjectLung non small cell canceren
dc.subjectInformation retrievalen
dc.subjectSurvivalen
dc.subjectCancer radiotherapyen
dc.subjectLomustineen
dc.subjectSample sizeen
dc.subjectData analysisen
dc.subjectStatistical analysisen
dc.subjectMitomycin cen
dc.subjectDisease associationen
dc.subjectLung canceren
dc.subjectIfosfamideen
dc.subjectCancer classificationen
dc.subjectEvaluationen
dc.subjectHealth statusen
dc.subjectAdvanced stageen
dc.subjectRandomised controlled trialsen
dc.subjectNon-small cellen
dc.subjectPerformance statusen
dc.subjectPlatinumen
dc.subjectSelection biasen
dc.subjectTaxaneen
dc.subjectVindesineen
dc.titleRandomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: Biases and evolution over timeen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/S0959-8049(03)00571-9
dc.description.volume39
dc.description.issue16
dc.description.startingpage2278
dc.description.endingpage2287
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record